Merus NV is a clinical-stage immuno-oncology company... Show more
The 50-day moving average for MRUS moved above the 200-day moving average on June 17, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on July 09, 2025. You may want to consider a long position or call options on MRUS as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRUS just turned positive on July 16, 2025. Looking at past instances where MRUS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRUS advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRUS broke above its upper Bollinger Band on July 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRUS entered a downward trend on July 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.794) is normal, around the industry mean (18.143). P/E Ratio (0.000) is within average values for comparable stocks, (58.647). MRUS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (76.336) is also within normal values, averaging (270.975).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of therapeutics for cancer treatment
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
IHOVX | 22.61 | 0.08 | +0.36% |
Hartford International Opportunities R6 | |||
VITAX | 351.31 | 0.25 | +0.07% |
Vanguard Information Technology Idx Adm | |||
CVFCX | 15.78 | N/A | N/A |
Victory Pioneer Disciplined Value A | |||
NWHHX | 15.24 | -0.03 | -0.20% |
Nationwide Bailard Cogntv Val Instl Svc | |||
AVUVX | 16.81 | -0.04 | -0.24% |
Avantis® U.S. Small Cap Value Instl |
A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with VIGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then VIGL could also see price increases.
Ticker / NAME | Correlation To MRUS | 1D Price Change % | ||
---|---|---|---|---|
MRUS | 100% | +2.96% | ||
VIGL - MRUS | 50% Loosely correlated | -0.12% | ||
CGON - MRUS | 49% Loosely correlated | N/A | ||
RVMD - MRUS | 48% Loosely correlated | -1.92% | ||
IDYA - MRUS | 48% Loosely correlated | -2.26% | ||
CRNX - MRUS | 45% Loosely correlated | -5.78% | ||
More |